Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Gross Profit (2018 - 2023)

Serina Therapeutics (SER) has disclosed Gross Profit for 6 consecutive years, with $55000.0 as the latest value for Q4 2023.

  • Quarterly Gross Profit rose 685.71% to $55000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $102000.0 through Dec 2023, up 385.71% year-over-year, with the annual reading at $102000.0 for FY2023, 385.71% up from the prior year.
  • Gross Profit hit $55000.0 in Q4 2023 for Serina Therapeutics, up from $34000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $470000.0 in Q4 2019 to a low of $4000.0 in Q1 2022.
  • Historically, Gross Profit has averaged $103350.0 across 5 years, with a median of $38000.0 in 2020.
  • Biggest five-year swings in Gross Profit: plummeted 92.45% in 2022 and later skyrocketed 750.0% in 2023.
  • Year by year, Gross Profit stood at $470000.0 in 2019, then tumbled by 67.45% to $153000.0 in 2020, then crashed by 83.01% to $26000.0 in 2021, then plummeted by 73.08% to $7000.0 in 2022, then skyrocketed by 685.71% to $55000.0 in 2023.
  • Business Quant data shows Gross Profit for SER at $55000.0 in Q4 2023, $34000.0 in Q3 2023, and $4000.0 in Q2 2023.